Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APGE |
---|---|---|
09:32 ET | 3206 | 58.13 |
09:34 ET | 700 | 59.0599 |
09:36 ET | 1335 | 57.915 |
09:56 ET | 100 | 57.8 |
09:57 ET | 1665 | 57.76 |
09:59 ET | 300 | 57.48 |
10:01 ET | 665 | 58.11 |
10:03 ET | 300 | 58.21 |
10:06 ET | 500 | 58.14 |
10:08 ET | 500 | 58.07 |
10:10 ET | 400 | 58.03 |
10:12 ET | 37361 | 58.07 |
10:15 ET | 200 | 57.67 |
10:17 ET | 1000 | 57.8142 |
10:19 ET | 100 | 57.785 |
10:21 ET | 1110 | 58.05 |
10:24 ET | 300 | 58.1 |
10:33 ET | 100 | 58.23 |
10:35 ET | 344 | 58.23 |
10:42 ET | 100 | 58.38 |
10:44 ET | 400 | 58.43 |
10:46 ET | 100 | 58.39 |
10:48 ET | 100 | 58.38 |
10:50 ET | 300 | 58.26 |
10:51 ET | 700 | 58.22 |
10:53 ET | 1146 | 57.99 |
10:55 ET | 30400 | 57.83 |
10:57 ET | 200 | 57.8 |
11:02 ET | 5557 | 57.58 |
11:04 ET | 600 | 57.69 |
11:06 ET | 100 | 57.72 |
11:08 ET | 1464 | 57.87 |
11:09 ET | 1700 | 57.9517 |
11:11 ET | 2900 | 57.985 |
11:13 ET | 500 | 58 |
11:18 ET | 350 | 58 |
11:20 ET | 200 | 58.205 |
11:24 ET | 300 | 58.2387 |
11:26 ET | 1456 | 57.89 |
11:27 ET | 1500 | 57.9894 |
11:31 ET | 200 | 58 |
11:33 ET | 100 | 57.98 |
11:36 ET | 500 | 57.985 |
11:38 ET | 250 | 58 |
11:40 ET | 200 | 57.96 |
11:42 ET | 100 | 58.02 |
11:44 ET | 300 | 58.03 |
11:45 ET | 100 | 58.01 |
11:49 ET | 600 | 58.055 |
11:51 ET | 200 | 58.26 |
11:54 ET | 200 | 58.24 |
12:00 ET | 1100 | 58.42 |
12:02 ET | 575 | 58.3 |
12:03 ET | 100 | 58.305 |
12:07 ET | 100 | 58.305 |
12:09 ET | 200 | 58.21 |
12:14 ET | 205 | 58.115 |
12:16 ET | 400 | 58.03 |
12:18 ET | 200 | 58.0575 |
12:20 ET | 100 | 58.045 |
12:32 ET | 100 | 58.075 |
12:36 ET | 900 | 58.27 |
12:38 ET | 200 | 58.27 |
12:39 ET | 300 | 58.46 |
12:43 ET | 463 | 58.29 |
12:45 ET | 100 | 58.26 |
12:57 ET | 200 | 58.32 |
12:59 ET | 100 | 58.235 |
01:03 ET | 300 | 58.33 |
01:06 ET | 100 | 58.315 |
01:08 ET | 500 | 58.255 |
01:17 ET | 500 | 58.29 |
01:21 ET | 200 | 58.3 |
01:26 ET | 1443 | 58.57 |
01:28 ET | 100 | 58.6 |
01:30 ET | 100 | 58.595 |
01:32 ET | 100 | 58.75 |
01:33 ET | 1866 | 58.65 |
01:35 ET | 200 | 58.52 |
01:37 ET | 200 | 58.46 |
01:39 ET | 343 | 58.19 |
01:42 ET | 200 | 58.075 |
01:44 ET | 600 | 58.09 |
01:48 ET | 900 | 58.405 |
01:50 ET | 100 | 58.43 |
01:51 ET | 100 | 58.415 |
01:53 ET | 200 | 58.51 |
01:55 ET | 400 | 58.485 |
02:00 ET | 500 | 58.375 |
02:04 ET | 100 | 58.41 |
02:09 ET | 319 | 58.27 |
02:11 ET | 300 | 58.385 |
02:20 ET | 100 | 58.24 |
02:22 ET | 100 | 58.3 |
02:24 ET | 200 | 58.18 |
02:26 ET | 200 | 58.185 |
02:27 ET | 100 | 58.08 |
02:31 ET | 300 | 57.89 |
02:40 ET | 300 | 57.83 |
02:42 ET | 150 | 57.795 |
02:49 ET | 100 | 57.89 |
02:51 ET | 300 | 57.9 |
02:54 ET | 675 | 57.94 |
02:56 ET | 17100 | 57.765 |
03:00 ET | 500 | 57.865 |
03:02 ET | 100 | 57.875 |
03:05 ET | 300 | 57.7 |
03:12 ET | 100 | 57.62 |
03:14 ET | 200 | 57.41 |
03:16 ET | 300 | 57.5 |
03:20 ET | 200 | 57.47 |
03:23 ET | 200 | 57.53 |
03:25 ET | 1009 | 57.55 |
03:27 ET | 300 | 57.6 |
03:32 ET | 100 | 57.635 |
03:34 ET | 100 | 57.69 |
03:36 ET | 200 | 57.64 |
03:39 ET | 200 | 57.684 |
03:41 ET | 1004 | 57.6175 |
03:43 ET | 100 | 57.54 |
03:45 ET | 700 | 57.59 |
03:48 ET | 800 | 57.7 |
03:50 ET | 543 | 57.75 |
03:52 ET | 643 | 57.8 |
03:54 ET | 700 | 57.94 |
03:56 ET | 400 | 57.91 |
03:57 ET | 7413 | 57.99 |
03:59 ET | 35393 | 58.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Apogee Therapeutics Inc | 3.0B | -25.8x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.1x | --- |
Celldex Therapeutics Inc | 2.9B | -12.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 3.1B | -5.7x | --- |
MoonLake Immunotherapeutics | 3.3B | -54.6x | --- |
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -25.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.